This review highlights the importance of balancing gastrointestinal and cardiovascular risks when prescribing NSAIDs, recommending PPIs and COX-2 inhibitors for optimal gastric protection.
PURPOSE OF REVIEW: This article reviews selected publications related to nonsteroid anti-inflammatory drug (NSAID)-induced gastroduodenal toxicity in recent years. RECENT FINDINGS: This article provides a comprehensive review of the latest evidence on the epidemiology of NSAID-induced gastroduodenal injury, recommendations on optimal gastroprotective regimens among patients in need of NSAID, risk stratification approach by considering gastrointestinal and cardiovascular risks, and negative interaction between proton pump inhibitors (PPIs) and clopidogrel. SUMMARY: Current evidence indicates that a PPI and a cyclooxygenase (COX)-2-selective NSAID provides the best gastric protection. In light of potential cardiovascular hazard of NSAIDs, physicians should select an NSAID according to individual patients' cardiovascular risk (i.e., naproxen vs. a nonnaproxen NSAID). The choice of gastroprotective therapy depends on the number and nature of gastrointestinal risk factors. PPI co-therapy is recommended in patients with high gastrointestinal risk on aspirin. Whether there is any clinically important interaction between PPIs and clopidogrel remains uncertain.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2009) conducted a review in NSAID-induced gastroduodenal injury. NSAIDs and gastroprotective regimens was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: